Glucoryl-MV1 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, each contributing distinct mechanisms to optimize blood glucose regulation. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing fasting and postprandial blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, improving insulin sensitivity without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, mitigating postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual and prolonged drug release, promoting better patient compliance and stable plasma drug concentrations. This combination is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy with either sulfonylurea or metformin. Glucoryl-MV1 should be used under medical supervision, with regular monitoring of blood glucose levels and renal function. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in cases of diabetic ketoacidosis or severe infections. Adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis.